After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Almost 1,200 people in Kern County have died from fentanyl overdoses since 2018, including 171 in 2024 and an all-time high of 294 the year before, according to updated numbers from the Kern ...

Thank you for standing by for the Alphabet fourth quarter and fiscal year 2024 earnings conference call. At this time, all ...

Google revealed several significant updates regarding its AI developments, coinciding with industry scrutiny surrounding ...

The problem seems to ... What kind of duvet cover do you pair with your sheets? It's best to choose a duvet cover with the same fabrication as your sheet set — if you like how your sheets ...

But the state has $400 million set aside in a special fund to cover shortfalls – and another ... using that money would just delay fixing the problem for the next three or four years.

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

The FDA has approved twice-daily Journavx for adults with moderate-to-severe acute pain. Vertex has set the wholesale acquisition cost (WAC) of the medication, the price set by a pharmaceutical ...

Alphabet's Q4 earnings show growth in key areas, but missed expectations, causing a dip. Read what makes GOOG stock an ...

Bruce Y. Lee, M.D., MBA, is a Senior Contributor for Forbes who has been covering health, medicine, wellness and science for Forbes since 2015. He is a journalist, professor, researcher ...